TCGA-50-8457-01A-11R-2326-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.280
- MYOGENESIS+0.280
- UV_RESPONSE_DN+0.270
- NOTCH_SIGNALING+0.240
- KRAS_SIGNALING_UP+0.220
- IL6_JAK_STAT3_SIGNALING+0.200
- TGF_BETA_SIGNALING+0.200
- WNT_BETA_CATENIN_SIGNALING+0.190
- HEDGEHOG_SIGNALING+0.180
- TNFA_SIGNALING_VIA_NFKB+0.160
Top 10 suppressed
- E2F_TARGETS-0.660
- G2M_CHECKPOINT-0.610
- MYC_TARGETS_V1-0.580
- MYC_TARGETS_V2-0.580
- MTORC1_SIGNALING-0.520
- OXIDATIVE_PHOSPHORYLATION-0.520
- GLYCOLYSIS-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.380
- DNA_REPAIR-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-A4P8-01A-11R-A24X-07 | — | cohortA1 | 0.944 |
| 2 | TCGA-55-A57B-01A-12R-A39D-07 | — | cohortA1 | 0.918 |
| 3 | ERR2208890 | — | — | 0.918 |
| 4 | TCGA-MP-A4TH-01A-31R-A262-07 | — | cohortA1 | 0.915 |
| 5 | TCGA-55-8513-01A-11R-2403-07 | — | cohortA1 | 0.915 |
| 6 | TCGA-86-A4P7-01A-11R-A24X-07 | — | cohortA1 | 0.913 |
| 7 | SRR8613762 | — | A | 0.910 |
| 8 | TCGA-97-8172-01A-11R-2287-07 | — | cohortA1 | 0.898 |
| 9 | C3L-03268 | — | cohortA1 | 0.891 |
| 10 | TCGA-93-A4JP-01A-11R-A24X-07 | — | cohortA1 | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.080 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |